Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of differing flap reconstruction strategies in perineal closure following advanced pelvic oncological resection: a retrospective cohort study.
Galbraith NJ, McCollum C, Di Mascio L, Lowrie J, Hinckley M, Lo S, Watson S, Telfer JRC, Roxburgh CS, Horgan PG, Chong PS, Quinn M, Steele CW. Galbraith NJ, et al. Among authors: di mascio l. Int J Surg. 2023 Nov 1;109(11):3375-3382. doi: 10.1097/JS9.0000000000000617. Int J Surg. 2023. PMID: 37678294 Free PMC article.
Management of lateral epicondylitis (tennis elbow).
Karbowiak M, Holme T, Thambyrajah J, Di Mascio L. Karbowiak M, et al. Among authors: di mascio l. BMJ. 2023 May 18;381:e072574. doi: 10.1136/bmj-2022-072574. BMJ. 2023. PMID: 37201946 No abstract available.
Reverse shoulder arthroplasty versus hemiarthroplasty versus non-surgical treatment for older adults with acute 3- or 4-part fractures of the proximal humerus: study protocol for a randomised controlled trial (PROFHER-2: PROximal Fracture of Humerus Evaluation by Randomisation - Trial Number 2).
Rangan A, Gwilym S, Keding A, Corbacho B, Kottam L, Arundel C, Coleman E, DiMascio L, Hewitt C, Jones V, Kassam J, McDaid C, Mitchell N, Mott A, O'Carroll G, Tharmanathan P, Torgerson D. Rangan A, et al. Trials. 2023 Apr 13;24(1):270. doi: 10.1186/s13063-023-07259-3. Trials. 2023. PMID: 37055816 Free PMC article.
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S, Tulsian NK, Gruber JJ, DiMascio L, Paszkiewicz KH, Ingram PJ, D Boyd-Kirkup J. Thakkar D, et al. J Immunother Cancer. 2022 Feb;10(2):e003382. doi: 10.1136/jitc-2021-003382. J Immunother Cancer. 2022. PMID: 35131861 Free PMC article.
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.
Maurice-Dror C, Le Moigne R, Vaishampayan U, Montgomery RB, Gordon MS, Hong NH, DiMascio L, Perabo F, Chi KN. Maurice-Dror C, et al. Invest New Drugs. 2022 Apr;40(2):322-329. doi: 10.1007/s10637-021-01202-6. Epub 2021 Nov 29. Invest New Drugs. 2022. PMID: 34843005 Clinical Trial.
37 results